According to TipRanks.com, Archila is a 5-star analyst with an average return of 11.4% and a 52.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

DelveInsight's FAP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Discover key insights from Arvinas, Inc.'s Q2 2025 earnings call, including CEO transition, clinical milestones, Pfizer partnership updates, and ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

Amarin Corporation AMRN reported a loss of 3 cents per share for the second quarter of 2025, which was significantly narrower ...